Clinical trial · Observational
Detection of Tumor DNA in Blood Samples From Cancer Patients
Detection of Tumor DNA in Blood Samples From Patients With Late Stage Cancer and "Healthy Controls"
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to employ genomic detection methodologies to measure the relative amount of tumor nucleic acids in the blood of a cancer patient with diagnosed metastatic disease that is either commencing, currently undergoing or completed cytotoxic chemotherapy treatment. More generally, this approach will allow us to develop a quantitative measure of therapy efficacy via the counting of the relative changes in tumor molecules over the course of treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Tumors | Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Stage II or III curative surgery (closed to accrual)
- description
- Patients with stage II or III solid tumors undergoing curative intend surgery enrolled before surgery.
- interventionNames
- Diagnostic Test: Blood test
- label
- Stage II or III neoadjuvant therapy cohort (closed to accrual)
- description
- Patients with stage II or III solid tumors undergoing neoadjuvant therapy followed by curative intend surgery enrolled before neoadjuvant therapy.
- interventionNames
- Diagnostic Test: Blood test
- label
- Metastatic disease
- description
- Patients with advanced, recurrent and/or metastatic disease requiring systemic therapy with chemotherapy, targeted therapy, immunotherapy or a combination of any before initiation of any therapy or a new line of therapy following documentation of disease progression on prior therapy.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years or older * Have metastatic disease with from a solid tumor (e.g. breast, lung, colon, pancreas, ovary, prostate...) or stage II or III solid tumors undergoing curative surgery or neoadjuvant therapy followed by surgery * Starting treatment or a new line of treatment * Able to understand and grant informed consent * Able to have their blood drawn Exclusion Criteria: * Unable to grant informed consent or comply with all study procedures. * Has a hematological malignancy, i.e. myeloma, lymphoma, MDS, leukemia
References
Publications (0)
Data not yet available